Haleos LabsNSE:HALEOSLABS -0.50%72 Interest Coverage is 0.22 as of Mar. 2026, which is 95% below its 10-year median of 4.10. GuruFocus rates NSE:HALEOSLABS with a GF Score™ of 72/100 and a GF Value™ of ₹1,123.78 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 376 Biotechnology companies, Haleos Labs ranks worse than 85.37% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Haleos Labs's
Operating Income
for the
three
months ended in Mar. 2026 was ₹3 Mil. Haleos Labs's Interest Expense for the
three
months ended in Mar. 2026 was ₹-14 Mil.
Haleos Labs's interest coverage for the quarter that ended in Mar. 2026 was 0.22.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Haleos Labs's Interest Coverage or its related term are showing as below:
NSE:HALEOSLABS'
s Interest Coverage Range Over the Past 10 Years
Min: 1.64 Med: 4.1 Max: 6.63
Current: 4.35
NSE:HALEOSLABS's Interest Coverage is ranked worse than 85.37% of 376
companies
in the Biotechnology industry
Industry Median: 110.86
vs NSE:HALEOSLABS: 4.35
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Haleos Labs Interest Coverage Related Terms
Haleos Labs Interest Coverage Historical Data
* Premium members only.
The historical data trend for Haleos Labs's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:HALEOSLABS vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Haleos Labs's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleos Labs Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Haleos Labs's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Haleos Labs's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleos Labs (NSE:HALEOSLABS) has a Interest Coverage of 0.22 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Haleos Labs and its competitors. This is 95% below median its historical median of 4.10. Over the past decade, Haleos Labs' Interest Coverage has ranged from 1.64 to 6.63. According to the industry distribution chart, Haleos Labs ranks #321 out of 376 companies in the Biotechnology industry, placing it in the top 85.4%.
Is Haleos Labs' Interest Coverage too high?
Haleos Labs' current Interest Coverage of 0.22 is 95% below median its 10-year median of 4.10. Over the past 10 years, this metric has ranged from a low of 1.64 to a high of 6.63. The Biotechnology industry median Interest Coverage is 110.86. Haleos Labs' value of 0.22 is 99.8% below this industry median. Based on the distribution chart, Haleos Labs ranks #321 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Haleos Labs has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Haleos Labs ranks #321 out of 376 companies for Interest Coverage. This places Haleos Labs in the lower half of its industry. The industry median Interest Coverage is 110.86. Haleos Labs' value of 0.22 is 99.8% below this benchmark. Historically, Haleos Labs' own Interest Coverage has ranged from 1.64 to 6.63 over the past decade. While the company's 10-year median is 4.10 vs. the industry median of 110.86, Haleos Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 110.86, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haleos Labs's current Interest Coverage of 0.22 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Haleos Labs and its competitors. For the Biotechnology industry, the median Interest Coverage is 110.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haleos Labs's current Interest Coverage is 0.22, which is 95% below median its own 10-year median of 4.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (NSE:HALEOSLABS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,123.78, compared to a current price of ₹1,612.30 — trading 43.5% above its estimated fair value. The current Interest Coverage is 0.22, which is 95% below median its 10-year median of 4.10 and 99.8% below the Biotechnology industry median of 110.86. Haleos Labs' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Haleos Labs (NSE:HALEOSLABS), the current Interest Coverage is 0.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleos Labs (NSE:HALEOSLABS) Overvalued in 2026?
Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued.
The current stock price of ₹1,612.30 is trading 43.5% above its estimated GF Value™ of ₹1,123.78.
GuruFocus considers Haleos Labs to be Significantly Overvalued.
Key valuation signals for NSE:HALEOSLABS:
Interest Coverage: 0.22 (95% below median its 10-year median of 4.10)
GF Value™: ₹1,123.78 vs. price of ₹1,612.30 (43.5% above fair value)
Industry Position: 99.8% below the Biotechnology median (#321 of 376)
No single metric tells the full story. See the NSE:HALEOSLABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
72GF Score
Get the complete analysis for NSE:HALEOSLABS
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HALEOSLABS has been successfully added to your 
